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ABSTRACT 
The renin-angiotensin-aldosterone system makes a critical contribution to body fluid 
homeostasis, and abnormalities in this endocrine system have been implicated in certain forms of 
hypertension.  The peptide hormone angiotensin II (AngII) regulates hydromineral homeostasis 
and blood pressure by acting on both peripheral and brain targets.  In the brain, AngII binds to the 
angiotensin type 1 receptor (AT1R) to stimulate thirst, sodium appetite and both arginine 
vasopressin (AVP) and oxytocin (OT) secretion.  The present work used an experimental model 
of endogenous AngII to examine the role of p44/42 mitogen-activated protein kinase (MAPK) as 
a signalling mechanism to mediate these responses.  Animals were given a combined treatment of 
furosemide and a low dose of captopril (furo/cap), a diuretic and an angiotensin converting enzyme 
inhibitor, respectively, to elevate endogenous AngII levels in the brain. Furo/cap induced p44/42 
MAPK activation in key brain areas that express AT1R, and this effect was reduced with either a 
centrally administered AT1R antagonist (irbesartan) or a p44/42 MAPK inhibitor (U0126). 
Additionally, furo/cap treatment elicited water and sodium intake, and irbesartan markedly 
reduced both of these behaviors.  Central injection of U0126 markedly attenuated furo/cap-induced 
sodium intake but not water intake.  Furthermore, p44/42 MAPK signalling was not necessary for 
either furo/cap- or exogenous AngII-induced AVP or OT release.  Taken together, these results 
indicate that p44/42 MAPK is required for AngII-induced sodium appetite, but not thirst or 
neurohypophysial secretion.  This result may allow for discovery of more specific downstream 
targets of p44/42 MAPK to curb sodium appetite, known to exacerbate hypertension, while leaving 
thirst and neurohypophysial hormone secretion undisturbed. 
 
 
Introduction 
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The renin-angiotensin-aldosterone system promotes body fluid homeostasis by 
coordinating physiological and behavioural responses to correct fluid perturbations (1, 2). 
Hypotensive and hypovolemic events prompt the release of the enzyme renin from the kidneys, 
which initiates a catalytic cascade that ultimately elevates blood levels of the hormone angiotensin 
II (AngII) (3).  Peripherally, AngII constricts blood vessels to support blood pressure.  Circulating 
AngII binds to brain receptors in the subfornical organ (SFO), organum vasculosum of the lateral 
terminalis (OVLT), brain regions with an incomplete blood-brain barrier.  In addition, AngII 
produced locally by the brain renin-angiotensin system acts on relays in the median pre-optic 
nucleus (MNPO), paraventricular nucleus of the hypothalamus (PVN) and supraoptic nucleus 
(SON) (4).  Acting upon these central nuclei, AngII prompts thirst, sodium appetite (5, 6), and 
both arginine vasopressin (AVP) and oxytocin (OT) secretion (7).  While the physiological actions 
of AngII are well known, our understanding of its cellular actions is incomplete. 
The central actions of AngII are mediated by the angiotensin type 1 receptor (AT1R), 
which belongs to the super family of G protein coupled receptors and associates with Gq to trigger 
inositol 1,4,5-triphosphate (IP3) production and Ca2+ mobilization (8, 9).  In vitro research 
uncovered a parallel signal transduction pathway that phosphorylates MAPK Kinase (MEK), 
which activates mitogen-activated protein kinase (MAPK) (10) , including the p42 and p44 
isoforms, also referred to as extracellular signal-regulated kinase 1 and 2.  In turn, p44/42 MAPK 
provokes a variety of downstream changes in cellular activity, such as changes in gene expression 
(11-13).  Although the majority of studies examining AT1R-induced p44/42 MAPK activation 
were performed in vitro, p44/42 MAPK activation also occurs in the SFO and PVN after a systemic 
AngII injection (14).  As these AT1R signalling molecules were detected in the brain, researchers 
have begun to investigate their role in the neural actions of AngII. 
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A previous study employed signalling selective AT1R ligands and inhibitors to reveal that 
the inositol triphosphate (IP3) branch of AT1R signal transduction mediates thirst, whereas the 
p44/42 MAPK signalling pathway mediates sodium appetite (15, 16).  This finding was novel and 
intriguing; however, it remained unclear whether the result reflected a normal physiological 
process or a pharmacological phenomenon based on exogenously administered AngII.  Therefore, 
to establish the physiological significance of AngII-induced p44/42 MAPK on sodium appetite, 
we exploited a preparation for endogenous AngII-induced sodium appetite (17).  More 
specifically, a combined treatment of furosemide and a low dose of captopril (furo/cap), a loop 
diuretic and an inhibitor of angiotensin converting enzyme (ACE) inhibitor, respectively, elevates 
brain levels of AngII.  The low dose of captopril blocks the conversion of diuresis-provoked 
angiotensin I to AngII in the periphery, but still allows conversion in circumventricular organs, 
which contain very high levels of ACE in comparison to the periphery (18). The high level of 
endogenous AngII production in the brain elicits rapid and robust thirst and sodium ingestion (19).  
We used this model to test the hypothesis that p44/42 MAPK phosphorylation mediates sodium, 
but not water, ingestion induced by endogenous AngII production.   
Given the myriad actions of AngII in the brain, it is important to consider the signalling 
pathways involved in other AngII-induced effects, such as neuroendocrine responses.  In 
addition to its effects on water and sodium ingestion, central AngII is a potent stimulus for AVP 
and OT secretion (20).  While AVP promotes renal water reabsorption, OT increases renal 
sodium excretion and centrally inhibits sodium appetite (21-23).  AT1R-expressing neurones 
in the SFO send axonal projections to the neurosecretory PVN and SON, where AVP and OT 
neuronal activity is increased to hormone release from the neurohypophysis  (24).  We addressed 
the role of p44/42 MAPK signalling in AngII-induced AVP and OT by measuring plasma levels 
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of the neurohypophysial hormones after either furo/cap treatment or icv AngII in the presence of 
an AT1R antagonist or MEK inhibitor.  Overall, our experiments better define the participation of 
p44/42 MAPK signalling in the regulation of fluid balance. 
 
Materials and Methods 
Animals 
Adult male Sprague-Dawley rats (n = 83) that weighed between 225-250 g were obtained 
from Charles River Laboratories (Wilmington, MA, USA).  Rats were pair-housed in plastic tubs 
with standard bedding and with food and water available ad libitum, except during experimental 
procedures.  The temperature in the colony was maintained at 22 °C with a 12:12 h reversed 
light/dark cycle.  Animals were allowed at least one week to acclimate to the colony before any 
procedures were performed.  The Institutional Animal Care and Use Committee of the University 
of Pennsylvania approved all procedures with animals. 
 
Drugs 
Furosemide (Abbott Laboratories, N. Chicago, IL) and captopril (SQ-14225, Bristol-
Meyers-Squibb Pharmaceutical Research Institute, Princeton, NJ) were administered 
subcutaneously (sc) at doses of 10 mg/kg and 5 mg/kg body weight, respectively, in 0.9% sterile 
saline. Equal volume 0.9% sterile saline was administered in control animals. The specific doses 
for each drug given intracerebroventricularly (icv) were as follows: 20 ng AngII (Bachem, King 
of Prussia, PA), 0.4 ug irbesartan (a generous gift from Dr. Sal Lucania, Bristol Myers Squibb), 2 
nmol U0126 dissolved in 10% DMSO (Promega, Madison, WI). Artificial cerebrospinal fluid 
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(aCSF; R&D Systems, Minneapolis, MN) plus 10% DMSO was administered icv as a vehicle 
control.  All injections were administered icv in a volume of 2 ul. 
Surgeries 
Surgeries were performed under asceptic conditions.  Animals were anaesthetised with a 
combination of ketamine and xylazine (70 and 5 mg/kg, respectively, intraperitoneally [ip]) before 
being fixed in a stereotaxic frame and implanted with 26-gauge guide cannulae (Plastics One, 
Roanoke, VA, USA) aimed at the lateral ventricle.  The coordinates (0.48 mm caudal to bregma, 
1.6 mm from mid-line and 4.2 mm ventral to dura mater) were chosen to allow an internal injection 
cannula to extend beyond the guide cannula into the ventricular space.  The cannulae were fixed 
in place with dental cement and bone screws, and the animals were allowed at least five days to 
recover before verification procedures were performed.  After surgery, animals were injected with 
yohimbine (0.11 mg/kg, Ben Venue Laboratories Bedford, OH) and orally administered Children’s 
Tylenol (30 mg/ml, McNeil PPC Inc, Fort Washington, PA).  Upon awakening, animals were 
singly housed. 
Five days after surgery and prior to undergoing experimental treatments, animals were tested 
for correct cannula placement and patency.  They were given an injection of 20 ng of AngII diluted 
in aCSF icv via a Hamilton syringe connected with PE-10 tubing to an injector that terminated 1 
mm beyond the guide cannula.  Animals were excluded from the experiment if they failed to 
demonstrate a drinking response in less than 30 seconds, consuming at least 3 ml of water, in two 
separate AngII challenges.  Animals began testing three days after the icv test injections. 
 
Enzyme Linked Immunosorbent Assays 
 Experiment 1. Animals were pretreated with either vehicle, irbesartan, or U0126 icv. 
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Fifteen minutes after the icv injection, they were given furosemide, sc, followed 10 minutes later 
by captopril, sc. Thirty minutes after the captopril injection, animals were rapidly decapitated 
without anaesthesia and the brains were flash frozen in hexane over dry ice.  Rats were not 
administered anaesthesia because it is known to increase phosphorylated p44/42 MAPK 
levels, which would compromise our results (25).  Micropunches (1 mm diameter) of the brain 
regions of interest (OVLT, SFO, PVN, SON, and primary somatosensory cortex) were obtained 
from 300-µm sections cut on a cryostat.  OVLT/SFO and PVN/SON punches were combined from 
each rat to ensure detectable levels for analysis.  The micropunched tissue samples were immersed 
in the lysis buffer provided in the Pathscan p44/42 MAPK Sandwich ELISA kit (Cell Signalling 
Technology, Danvers, MA) plus 1 mM phenylmethanesulfonylfluoride (Sigma, St Louis, MO).  
The brain tissue samples were sonicated three times for one second (incubated on ice between 
bursts) followed by centrifugation at 14,000 rpm at 4C for 10 minutes.  Supernatant was collected 
and a protein assay was performed on five microliters of each sample.  Based on the protein levels 
detected by Bicinchoninic Acid Assay, appropriate amounts of lysis buffer, sample, and sample 
diluent were mixed for each sample.  This mixture (100 µl) was loaded into corresponding wells 
in both the Total and Phospho p44/42 MAPK Sandwich ELISA kits. The ELISA was performed 
according to the protocol provided by each kit. 
 
Behavioural Study 
For behavioural experiments, rats were removed from their home cages approximately one 
hour before the onset of the dark phase.  The rats were weighed and then placed in individual wire 
mesh-bottomed cage equipped with a funnel and calibrated tube for the collection of urine, and 
with two 25-ml bottles available for drinking tap water and 1.5% saline, each marked with 0.2 ml 
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graduations.  The rats were allowed to acclimate for one hour before the experiment began.  After 
the last drug treatment was given, water, saline, and urine levels were measured at 15 min intervals 
for the first hour and then at 30 min intervals for the remaining time. 
 Experiment 2A. The goal of the first behavioural experiment was to examine the role of 
p44/42 MAPK activation in mediating the effects of endogenous AngII on water and sodium 
intake.  The animals were assigned to one of four treatments in a crossover design, which allowed 
each rat to receive all treatment conditions over the course of the study without all the 
animals receiving the drug combinations in the same order.  The control condition was two 
vehicle injections (0.9% saline, sc) with a 10-min interval between them.  All other treatments 
included injections of furosemide and, 10 min later, captopril.  Icv injections were given 15 minutes 
before the furosemide injection.  Fluid ingestion was measured for three hours when animals 
were given furo/cap or saline.  Based on this initial study, it was noted that the induced 
ingestion mainly occurred within the first 90 minutes; therefore, subsequent studies used this 
time course.  To assess the role of AT1R, animals were treated with irbesartan icv, and to assess 
the role of p44/42 MAPK, they were injected with U0126 icv.  Water and 1.5% saline intakes as 
well as urine output, were measured for 90 minutes. 
Experiment 2B. The goal of the second behavioural experiment was to examine the role 
of p44/42 MAPK activation on water intake in the absence of sodium ingestion.  The animals were 
treated with either vehicle or U0126 icv followed 15 minutes later by furosemide, and 10 minutes 
later by captopril in a crossover design.  Rather than being presented with two bottles, as in the 
first experiment, animals were presented with a single bottle containing tap water.  Water intake 
was monitored for the next 90 minutes. 
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AVP and OT Secretion 
Experiment 3A.  Rats were pretreated centrally with either vehicle, irbesartan, or U0126, 
followed by either vehicle or furo/cap, sc as described above. Thirty minutes after the captopril 
injection rats were rapidly decapitated and trunk blood was collected into 10 ml BD Vacutainer 
blood collection heparinised glass tubes on ice (Franklin Lakes, NJ).  The thirty-minute time point 
was chosen based on the emergence of diuresis and drinking behaviour in our initial furo/cap 
studies.  Additionally, the ELISA study showed that U0126 effectively inhibited p44/42 MAPK 
activation at this time point.  Previous research examined a ninety-minute time point after furo/cap 
treatment, but did not observe increases in oxytocin (19).  The tubes then were centrifuged at 4oC 
at 1300 relative centrifugal force (rcf) for 10 min.  The plasma supernatant was extracted with 
acetone and petroleum ether.  Plasma levels of AVP and OT were measured with a specific 
radioimmunoassay performed by the laboratory of Dr. Joseph G. Verbalis, as described previously  
(26) .  The standard curve for each peptide was linear between 0.5 and 10.0 pg per tube with the 
use of a synthetic AVP and between 0.25 and 5 µU per tube with the OT standard (Bachem 
Americas, Inc, Torrance, California).  The minimum detectable concentration of AVP or OT in 
extracted plasma was 0.5 pg/ml and 0.25 µU/ml, respectively.  The AVP antiserum (R-4) displayed 
< 1% cross-reactivity with OT, and the OT antiserum exhibited < 1% cross-reactivity with AVP. 
Experiment 3B.  Rats were assigned to one of the following pretreatment groups: vehicle 
or U0126 (1mM) followed 15 minutes later by AngII (20 ng) icv.  Two or fifteen minutes after the 
last icv injection, rats were rapidly decapitated and their trunk blood was collected. The two- and 
fifteen-minute time points were based on the emergence of drinking behaviour in previous 
exogenous AngII studies and selected to establish the range of neurohypophysial hormone levels 
in the plasma after the treatments. Previous studies used a 90-second time point and observed 
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increases in plasma vasopressin  (27) .  The protocol described in Experiment 3A was then 
followed to measure AVP and OT levels.  
  
Statistical Analysis 
Data are presented as the mean ± the standard error of the mean.  For the behavioural 
studies, comparisons were made between the treatment conditions and over time using repeated 
measure analysis of variance (two-way ANOVA; time point x treatment).  For the p44/42 MAPK 
ELISA and AVP/OT radioimmunoassay results, comparisons were made between the treatment 
groups (one-way ANOVA).  When warranted, planned comparison post-hoc t-tests were 
performed.  All hypothesis tests used =0.05 as the criterion level of significance.  Statistical 
analyses were conducted using Prism 2.0 software (La Jolla, CA).  
 
Results 
Furo/cap treatment activates p44/42 MAPK in the brain 
 In Experiment 1, rat brain punches were collected from coronal slices for several brain 
regions, namely, OVLT, SFO, PVN SON and primary somatosensory cortex as a control brain 
region (depicted in Figure 1).  As shown in Figure 2A, total p44/42 MAPK levels between all of 
the treatment groups in the OVLT/SFO were not different (ANOVA F(5,19) = 0.5, p>0.05).  
However, p44/42 MAPK phosphorylation in the OVLT/SFO differed between treatment groups 
(ANOVA (F(5,19) = 5.9, p<0.01).  More specifically, furo/cap treatment increased phospho 
p44/42 absorbance levels compared to control (1.6  0.0 vs 1.1  0.1, p<0.001).  Furo/cap treatment 
paired with icv AT1R antagonist irbesartan or MEK inhibitor U0126 significantly reduced 
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absorbance levels compared to furo/cap with vehicle pretreatment (1.1  0.1  vs 1.1  0.0 vs 1.6  
0.0, respectively; p<0.01).   
 Likewise, Figure 2B illustrates that total p44/42 MAPK levels were equivalent for all 
treatment groups in the PVN/SON (ANOVA F(5,19) = 0.2, p>0.05).  However, p44/42 MAPK 
phosphorylation in the PVN/SON of the hypothalamus differed between treatment groups 
(ANOVA F(5,19) = 10.4, p<0.001).  In particular, furo/cap treatment augmented phospho p44/42 
absorbance levels compared to control (1.7  0.1 vs 1.1  0.0, p<0.001).  Pretreatment with either 
icv irbesartan or U0126 reduced absorbance levels of phospho p44/42 MAPK compared to 
furo/cap with vehicle pretreatment (1.2  0.1 vs 1.0  0.1 and 1.7  0.1, respectively; p<0.001).  
 As shown in Figure 2C, the control brain region S1 had similar levels of p44/42 total 
MAPK regardless of treatment group (ANOVA (F(5,19) = 0.4, P>0.05).  Unlike OVLT/SFO and 
PVN/SON, S1 did not show an increase in p44/42 MAPK phosphorylation in response to furo/cap 
treatment (ANOVA F(5,19) = 0.1, P>0.05).  
 
The role of p44/42 MAPK in furo/cap-induced water and sodium ingestion 
 Consistent with previous work (19), the furo/cap protocol produced a rapid diuresis and 
prompt water and sodium ingestion (as shown in Figure 3).  A two-way ANOVA established a 
strong main effect of furo/cap treatment on urine output (F(1, 112) = 72.4, p<0.0001).  Animals 
that received furo/cap treatment excreted significantly more urine during the three hours after 
treatment than controls (13.6 ± 1.1 versus 2.9 ± 0.5 ml, p<0.001).  This increase in urine output 
was first significant within 15 minutes of treatment (p<0.01).  These animals also drank water 
robustly in response to the furo/cap treatment compared with controls (F(1,112) = 23.5, p<0.001; 
7.8 ± 1.4 versus 0.8 ± 0.2 ml, p<0.001).  In addition, furo/cap-treated rats consumed substantial 
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amounts of 1.5% NaCl solution compared with controls during this three hour time period 
(F(1,112) = 9.0, p<0.01; 5.7 ± 1.5 versus 0.7 ± 0.2 ml, p<0.001).  The time point at which the 
furo/cap group intake became significantly elevated compared with the control group was 45 min 
for water intake (p<0.01) and 60 min for sodium intake (p<0.05) after the captopril injection. 
 Experiment 2A verified that furo/cap-induced water and sodium ingestion could be 
attributed, at least in part, to AT1Rs.  In particular, rats were pretreated centrally with the AT1R 
antagonist irbesartan (200 ng/ul) 15 min before furo/cap treatment  (28) .  A two-way ANOVA 
established a main effect of irbesartan on furo/cap induced water intake compared to furo/cap 
controls (F(1,275) = 11.2, p<0.01).  A similar main effect occurred with irbesartan treatment and 
furo/cap-induced sodium intake (F(1,270) = 9.2, p<0.01).  As shown in Figure 4A, irbesartan 
pretreatment decreased furo/cap-induced water intake by 50% over 90 minutes (5.8 ± 0.6 versus 
2.9 ± 0.5 ml, p<0.001), first becoming significant at 45 minutes (p<0.001).  Sodium intake was 
reduced by 56% at 90 minutes (4.6 ± 0.6 versus 2.0 ± 0.5 ml, p<0.001), first becoming significantly 
attenuated at 45 minutes (p<0.01).  This level of suppression of furo/cap-induced water and sodium 
intake by an AT1R antagonist is consistent with previous findings (19).   
 Next, we investigated whether furo/cap-induced water and sodium ingestion could be 
attributed, at least in part, to p44/42 MAPK signalling.  In particular, rats were pretreated centrally 
with the MEK inhibitor U0126 15 min before the furo/cap treatment.  The dose of U0126 was 
chosen based on previous efficacy (15), and was validated in our Experiment 1.  A two-way 
ANOVA did not reveal a main effect of U0126 on furo/cap-induced water intake compared to 
controls (F(1,275) = 2.5, p = 0.1).  However, there was a significant interaction between treatment 
and time (p<0.01).  U0126 decreased furo/cap-induced water intake by 30% at 90 minutes (5.8 ± 
0.6 versus 4.1 ± 0.5 ml, p< 0.01), as shown in Figure 4A.  A two-way ANOVA revealed a main 
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effect of U0126 on furo/cap-induced sodium intake (F(1,280) = 13.0, p<0.001).   U0126 reduced 
sodium intake by 60% (4.5 ± 0.6 versus 1.8 ± 0.5 ml, p < 0.001), first becoming significant at 30 
min (p<0.05).  Urine volume measurement confirmed that neither irbesartan or U0126 
pretreatment the interfered with the diuretic effectiveness of the furo/cap treatment (12.3 ± 
0.9 versus 12.4 ± 1.4 versus 14.0 ml, respectively; data not shown). 
 Previous work that suggested that p44/42 MAPK signalling mediates AngII-induced 
sodium appetite but not thirst; however, we observed a reduction in water intake in the U0126-
treated animals, albeit not until the 90-min time point.  We reasoned that this delayed suppression 
of water intake was an artefact of the two-bottle test, given that consumption of hypertonic saline 
would provide an osmotic stimulus for water intake.  Thus, as U0126 suppresses sodium ingestion, 
it may indirectly effect to reduce water intake.  This interpretation of the data is supported by the 
fact that U0126 suppressed sodium intake at 30 min, and subsequently reduced water intake at 90 
min.  To test this hypothesis, the effect of U0126 was examined in a single-bottle test.  In this case, 
a two-way ANOVA revealed that water intake was not significantly decreased with U0126 
treatment (F(1,105) = 1.2, p = 0.3), compared with animals only treated with furo/cap.  Furo/cap 
versus furo/cap + U0126 groups drank 4.3 ± 0.8 versus 5.0 ± 0.9 ml, respectively, at the 90-minute 
time point (Figure 4B).  
 
The role of p44/42 MAPK in furo/cap- and AngII-induced AVP and OT release 
 Experiment 3A investigated whether or not p44/42 MAPK signalling mediated furo/cap-
induced AVP and OT secretion.  Rats were pretreated with vehicle, irbesartan, or U1026 icv paired 
with either vehicle or furo/cap sc.  Thirty minutes after captopril treatment, plasma AVP levels 
differed between treatment groups (Figure 5; ANOVA (F(5,19) = 6.2, P<0.01).  Post hoc analysis 
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revealed that furo/cap stimulated AVP compared to vehicle treatment (1.3  0.2 vs 0.6  0.1 pg/ml, 
p<0.05).  However, when animals were pretreated centrally with irbesartan or U0126, furo/cap-
induced AVP secretion was not significantly reduced compared with vehicle pretreatment (1.4  
0.1 vs 1.7  0.3 vs 1.3  0.2 pg/ml, p>0.05).  Similarly, OT levels differed between groups thirty 
minutes after captopril treatment (ANOVA (F(5,19) = 3.3, P<0.05).  Post hoc evaluation indicated 
that furo/cap stimulated OT compared to control (5.6  1.0 vs 1.8  0.5 pg/ml, p<0.05). However, 
furo/cap treatment paired with irbesartan or U0126 centrally did not reduce OT levels compared 
to furo/cap with vehicle pretreatment (6.0  1.6 vs 4.7  0.9 vs 5.6  1.0 pg/ml, p>0.05). 
 In Experiment 3B, rats were pretreated centrally with either vehicle or U0126 followed 
by AngII (20 ng).  Two or fifteen minutes after treatment, plasma AVP differed between the groups 
(Figure 6; ANOVA (F(2,38) = 5.6, p<0.01).   Given that there were no significant differences 
between the two and 15 min time points within each treatment group, these data were combined. 
Post-hoc analysis indicated that AngII treatment stimulated AVP secretion compared with vehicle 
treatment (2.5 ± 0.3 versus 1.5 ± 0.2 pg/ml, p<0.01).  This level of AngII-induced AVP secretion 
is consistent with previous findings (29) .  However, when animals were pretreated with U0126, 
the AngII-induced AVP secretion was not significantly different than when AngII was given alone 
(2.3 ± 0.2 versus 2.5 ± 0.3 pg/ml, p = 0.7).  Likewise, plasma OT levels was increased 2 and 15 
min after AngII treatment compared with vehicle (Figure 6; ANOVA F(2,35) = 5.3, p<0.01).  Post 
hoc analyses revealed that AngII treatment stimulated OT secretion compared with vehicle 
treatment at levels congruous with previous findings (14.2 ± 2.8 versus 6.0 ± 1.3 pg/ml, p<0.01) 
(29) .  However, AngII-induced OT secretion was not diminished by U0126 pretreatment (14.2 ± 
2.8 versus 13.5 ± 2.4 pg/ml, p = 0.9). 
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Discussion   
 The goal of our experiments was to uncover the role of p44/42 MAPK in both behavioural 
and physiological actions of central AngII.  Experiment 1 demonstrated p44/42 MAPK activation 
in certain brain regions after endogenous AngII production, which was inhibited by an AT1R 
antagonist.  Experiment 2 established that endogenous AngII production promotes sodium 
appetite, but not thirst, via p44/42 MAPK activation.  Experiment 3 found that p44/42 MAPK 
activation does not mediate furo/cap- or AngII-induced AVP and OT secretion, underscoring the 
selective role of p44/42 MAPK in AngII-induced sodium appetite.  
While previous findings have demonstrated the part played by p44/42 MAPK in AngII-
induced sodium appetite, our studies confirm and extend these results (16).  For example, although 
studies using exogenous AngII-induced sodium appetite demonstrated the stimulation of p44/42 
MAPK activation by AngII, they did not show its reduction by MEK inhibitor U0126 in relevant 
brain regions (15, 16).  The present studies demonstrate that furo/cap induces p44/42 MAPK 
activation in relevant forebrain areas, and that our doses of central irbesartan and U0126 restore 
phosphor p44/42 MAPK to control levels.  The furo/cap treatment produces high levels of 
circulating renin and angiotensin I, and central AT1R appears to mediate a large proportion of the 
observed water and sodium ingestion  (19, 30) .  The present results further support the notion that 
AT1R-p44/42 MAPK activation is responsible for the increase in sodium appetite observed in our 
experiments, and that the reduction of the behaviour by U0126 is due to decreased p44/42 MAPK 
activation in relevant AT1R containing brain regions.  Moreover, our studies provided an 
additional control to examine the unique role of p44/42 MAPK in sodium appetite through use of 
a single water bottle test.  
Nevertheless, our studies present their own limitations.  For example, AngII levels in 
 15 
the brain may be unusually elevated by the peripheral blockade of angiotensin I conversion using 
the furo/cap model.  However, in this protocol AngII production is constrained by physiological 
availability of the prohormone  (19) .  Another consideration is that furo/cap treatment may activate 
other interoceptive systems apart from the renin-angiotensin-aldosterone system.  For example, 
low- and high-pressure baroreceptors would detect the diuresis-induced loss of blood volume and 
pressure, respectively, and relay this information to brainstem structures that may promote thirst, 
sodium appetite, or both (17) .  Such baroreceptor-mediated signals may explain the partial effect 
of irbesartan pretreatment on water and sodium intake, and its ineffectiveness on AVP and OT 
secretion.  Another limitation of our studies is the combining of brain regions for the p44/42 
MAPK ELISA.   An immunohistochemical approach would allow for better localization of 
activated p44/42 MAPK.  However, the objectivity, reproducibility, and semi-quantitative 
nature of ELISAs offer a clear advantage over the challenges of quantifying 
immunohistochemistry.   Lastly, the icv injections used in our studies are not as spatially 
discrete as parenchymal injections.  Future studies using local microinjections will be 
informative to pinpoint the contribution of parallel signalling pathways in specific brain 
regions. 
While demonstrating that AT1R-MAPK mediates sodium appetite, our studies indicate that 
water intake and the secretion of AVP and OT do not require p44/42 MAPK activation. Circulating 
AngII accesses AT1R located on neurones in the circumventricular organs, such as the SFO and 
the OVLT (4) , whose neurones project to the magnocellular neurones in the PVN and SON, which 
also express AT1R  (14, 24) .  Centrally administered AngII induces c-Fos expression in the PVN 
and SON and increases the firing rate of AVP and OT neurones  (31, 32) , resulting in plasma 
levels of these hormones being elevated within minutes after AngII injection  (33) .  These 
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hormones contribute to fluid balance, with AVP prompting water retention and OT 
stimulating natriuresis  (21, 23).   In furo/cap-treated animals, the AT1R antagonist irbesartan 
does not reduce AVP and OT secretion, which suggests that other mechanisms, such as 
baroreceptors, trigger neurohypophysial release in this circumstance.  However, it is possible that 
a role for AT1R and m44/42 MAPK in furo/cap-induced AVP and OT release could be found 
at different time points.  
The present study focused on a subset of the MAPK family, namely p44/42.  The role of 
other MAP kinases in the central effects of AngII remains unclear.  It is possible that p38 MAPK 
and/or JNK play a role in mediating the central actions of AngII not blocked by the p44/42 MAPK 
inhibitor.  Additionally, as shown in previous studies, it is possible for some MAP kinases, but not 
others, to be involved in mediating central AngII effects, such as AT1R upregulation (14).  It 
would be important for future studies to investigate the role of other MAP kinases in drinking 
behaviour and neurohypophysial release. 
Studying the signalling molecules involved in the central actions of AngII is the first step 
to understanding how central AngII exerts its physiological effects, but much remains to be 
uncovered about the cellular mechanisms by which they mediate these actions.  For example, there 
are several plausible mechanisms by which p44/42 MAPK may mediate sodium appetite in the 
brain.  One possibility is that AngII-MAPK signalling elicits sodium appetite by changing neuronal 
excitability in circumventricular neurones or forebrain integration sites that project to motor 
generators involved in salt ingestive behaviour  (4, 34) .  This rapid effect on synaptic transmission 
could explain the relatively fast time course of furo/cap-induced sodium appetite  (35) . 
Alternatively, p44/42 MAPK may be involved in long-term gene transcription and protein 
synthesis for sodium and potassium channel subunits or AT1R.  For example, MAPK up-regulates 
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AT1R in the SFO and PVN, and increased levels of AngII binding to its receptor may explain the 
robust sodium appetite, although not the lack of p44/42 MAPK-mediated water ingestion (14).  
Other downstream consequences of p44/42 MAPK activation include rearrangements of the 
cytoskeleton, which could include structural neural plasticity  (36, 37) .  This mechanism is 
highlighted in a study by Swank and Sweatt, which found that p44/42 MAPK activation is 
important for plasticity in taste learning  (38) .  Other research has demonstrated that sodium 
appetite is associated with dendritic growth and the development of dendritic spines in the nucleus 
accumbens  (39) .  p44/42 MAPK activation may underlie strengthened connections within this 
brain region associated with incentive sensitization, which would explain the sudden avidity for 
sodium.  It will be imperative for future studies to discern what downstream consequences of 
p44/42 MAPK signalling contribute to AngII-induced sodium appetite, keeping in mind there may 
be several parallel mechanisms.  
Extending beyond drinking behaviours and neurohypophysial secretion, central AngII has 
a multitude of actions in the brain.  For example, AngII causes sympathetic stimulation, 
hypothalamic-pituitary-adrenal activation, increased sympathetic tone, and ultimately an increase 
in mean arterial pressure (1).  Other investigators have begun to uncover the AT1R signalling 
mediating these actions.  Specifically, Wei et al have shown that p44/42 MAPK mediates the effect 
of central AngII to increase sympathetic nerve activity in heart failure, another syndrome 
adversely affected by salt intake  (40).  An important avenue for future investigation is to 
determine the locus within the network of AngII-modulated neural circuitry wherein sodium 
appetite and sympathetic activity share a common dependence on p44/42 MAPK activation. 
Another key question to address is the effect of elevated p44/42 MAPK activity in specific brain 
regions on the many central actions of AngII. 
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In summary, these studies provide new evidence that the diverse effects of central AngII 
rely on divergent signalling mechanisms.  More specifically, we found that sodium appetite 
requires p44/42 MAPK activation, whereas thirst and neurohypophysial hormone secretion do not.  
It will be important for future studies to assess the role of both p44/42 MAPK and other MAPK 
kinases in other central AT1R actions that remain undefined, such as hypothalamic-pituitary-
adrenal activation.  Moreover, it will be critical to find the downstream targets of MAPK and 
determine the cellular mechanism of AngII in exerting these central effects.  
 
Perspectives 
Elements of the renin-angiotensin-aldosterone system are frequently implicated in the 
pathogenesis of hypertension, although the cause of hypertension is often unknown (7).  
Hypertension is a common and serious health concern  (41).  One in three adults have chronically 
elevated blood pressure, which shortens a person’s life span by three to five years  (42) . The 
identification of signalling-selective subsets of AngII action in the brain presents an opportunity 
to more precisely target central pathways that regulate blood pressure  (43, 44) .  
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Figure Legends 
Figure 1. Drawing of a coronal hemi section of rat brain depicting the brain regions of interest for 
p44/42 MAPK activation assays.  Circles within each brain region represent 1 mm micropunches 
collected for the p44/42 MAPK ELISAs. The brain regions examined include circumventricular 
organs OVLT and SFO, as well as the PVN and SON of the hypothalamus.  Additionally, the S1 
was collected as a control brain region to assay P44/42 MAPK activation.   
Abbreviations: S1 = primary somatosensory cortex, CPu = caudate putamen, MS = medial septal 
nucleus, OVLT = organum vasculosum of the lateral terminalis, SFO = subfornical organ, fi = 
fimbria of the hippocampus, ic = internal capsule, PVN = paraventricular nucleus of the 
hypothalamus, SON = supraoptic nucleus of the hypothalamus. 
 
Figure 2. Bar graphs illustrating the levels of total p44/42 MAPK and phospho p44/42 MAPK in 
the OVLT/SFO (panel A), PVN/SON (panel B), and S1 (panel C) after either vehicle or furo/cap 
treatment sc and either vehicle, irbesartan, or U0126 administered icv (n = 3-5/group).  Total 
p44/42 MAPK levels do not change, whereas furo/cap treatment increases phosphorylated p44/42 
MAPK in the OVLT/SFO and PVN/SON, but not in S1. Both irbesartan and U0126 prevent this 
furo/cap induced increase in p44/42 MAPK phosphorylation. Abbreviations: OVLT = organum 
vasculosum of the lateral terminalis, SFO = subfornical organ, PVN = paraventricular nucleus of 
the hypothalamus, SON = supraoptic nucleus of the hypothalamus, S1 = primary somatosensory 
cortex. 
 
Figure 3. Line graphs illustrating the effect of furo/cap treatment on urine volume (panel A) and 
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water and sodium intake during a two-bottle test (panel B). On the x axis, zero minutes represents 
the time of captopril injection. Compared with vehicle treatment, rats given furo/cap treatment 
excreted significantly more urine within 15 minutes (n=16). Furo/Cap also induced a robust intake 
of water and 1.5% sodium within 45 minutes and 60 minutes of treatment, respectively. Asterisks 
indicate that p<0.01 when comparing Furo/Cap to vehicle treatment. 
 
Figure 4.  Line graphs illustrating the effect of blocking AT1R receptors and MAPK activation 
after furo/cap treatment in a two bottle test (panel A) and in a one bottle test (panel B).  On the x 
axis, zero minutes represents the time of captopril injection. In the two bottle test, compared with 
Furo/Cap + Vehicle treatment, rats given the Furo/Cap + AT1R antagonist irbesartan treatment 
consumed significantly less water within 45 minutes after treatment (n=28).  Irbesartan also 
reduced the intake of 1.5% saline within 45 minutes of treatment.  Compared with Furo/Cap + 
vehicle treatment, rats given Furo/Cap + the MEK inhibitor U0126 treatment consumed 
significantly less water within 90 minutes after treatment and significantly less saline within 30 
minutes of treatment (n=28).  In the one bottle test, compared with vehicle treated, rats given the 
MEK inhibitor U0126 treatment consumed similar amounts of water (n=12). Asterisks indicate 
that p<0.05 when comparing to Furo/Cap + Veh treatment. Stats for Furo/Cap + Veh compared 
to Veh are shown in Figure 3. 
 
Figure 5. Bar graphs illustrating the role of p44/42 MAPK activation on Furo/Cap-induced 
neurohypophysial secretion.  Plasma AVP (Panel A) and OT (Panel B) after vehicle or Furo/Cap 
treatment combined with either vehicle, irbesartan, or U0126 administered icv (n= 3-5/group). 
Furo/Cap-induced AVP and OT secretion was not diminished with either the AT1R antagonist 
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irbesartan or the MEK inhibitor U0126.  Abbreviations: AVP = arginine vasopressin, OT = 
oxytocin.  
 
Fig 6. Bar graphs illustrating the effect of inhibiting p44/42 MAPK activation on AngII-induced 
neurohypophysial hormone secretion.  Plasma AVP (Panel A) and OT (Panel B) levels two and 
fifteen minutes after icv Veh, AngII, or U0126 plus AngII (n = 10-16/group).  AngII-induced AVP 
and OT levels were not inhibited with the MEK inhibitor U0126. Abbreviations: AVP = arginine 
vasopressin, OT = oxytocin. 
 
